Fertility preservation in breast cancer patients
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Breast cancer is the most common malignancy in
women as it currently represents 15.2% of all
new cancer cases in the United States with
268,600 estimated new cases in 2019 [1]. Under
45 years of age, the percentage of new cases is
10.3% as it is the most common of all in women
of childbearing age. Due to the increasingly
advanced diagnostic and therapeutic techniques,
the mortality rate remains low in recent years.
For stages I and II, the 5-year survival is estimated
to be respectively 95% and 85–70%
(depending on whether they are IIA and IIB),
while in advanced stages, survival rates are
between 18 and 52% (for stages IIIA and B) [1].
Because the number of young cancer survivors
is increasing and as women tend to have
children in later reproductive ages, increasing
attention has been paid to chemotherapy-related
ovarian toxicity [2]. Most women with breast
cancer are likely to undergo neoadjuvant or adjuvant
chemotherapy that may result in premature
ovarian failure and infertility [3–5].
Açıklama
Anahtar Kelimeler
Kaynak
Female and Male Fertility Preservation
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Marin, L., Turan, V. & Oktay, K. (2022). Fertility preservation in breast cancer patients. Female and Male Fertility Preservation içinde (pp. 185-198). https://doi.org/10.1007/978-3-030-47767-7_14
